The Effects of a Nitrate Supplementation on Erectile Function

NCT ID: NCT06213077

Last Updated: 2024-01-19

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-12-12
• Study Completion Date: 2024-05-30

Brief Summary

Twenty (20) individuals to be recruited from Ballantyne Medical Associates in Charlotte, NC, without any significant chronic medical history. These patients are general patients for primary care that meet inclusion criteria. Patients will be screened and enrolled by Dr. Bauer and his delegated research staff upon patient consult. Patients will be informed of the purpose of the study including risks, benefits, and alternative treatments to the study. After the potential participants have been given the opportunity to ask questions and have their questions answered, they will be asked to sign an informed consent prior to any study-specific procedures being performed.

Blinded test product will be randomly assigned to study subjects. Test group 1 will be dosed with a placebo capsule taken two capsules once daily Test group 2 will be dosed with Berkeley Life capsules taken two capsules once daily. At baseline, prior to crossover to the other treatment, and at the study's conclusion, NO levels will be monitored using salivary nitric oxide test strips. Both test groups will remain on their existing treatment protocol throughout the study.

Detailed Description

Patients will be consented and enrolled in the study. A complete medical history and focused physical examination will be conducted and documented and NO levels will be measured using salivary test strips.

Twenty (20) patients with low NO levels will be enrolled and will be randomly assigned to group 1 or group 2.

Once enrolled, patients will be required to complete a subjective questionnaire (the International Index of Erectile Function (IIEF)), EHS Score questionnaire and a Quality of Life (QOL) survey. Patients will be instructed to take 2 Berkeley Life capsules once daily or the placebo based on randomization. The (IIEF) was developed by Rosen and colleagues in 1997 as a multidimensional, 15-item, self-administered questionnaire with the goal of assessing five domains of male sexual function including erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction. The erectile function domain of the IIEF (IIEF-EF) contains 6 questions which the patient answers on a scale from 1 (never or almost never) to 5 (almost always or always), providing a total score of 6 to 30 points. The questions concern erectile frequency, firmness, penetration ability, maintenance frequency, maintenance ability, and erection confidence. Based on a controlled study of 1,151 men taking sildenafil in order to establish cutoff scores for the IIEF-EF, a score of 26 or greater is defined as normal function, mild ED is a score from 22 to 25, mild to moderate ED 17 to 21, moderate ED 11 to 16, and severe ED 6 to 10.

Patients will be sent home with instructions to take 2 Berkeley Life capsules once daily in combination with their existing treatment protocol and then return on day 60, returning all unused test product.

The subject should be willing to self-administer 2 capsules daily and be willing to, upon waking in the AM, self-test with strip and record on a pre-print sheet the test strip color, followed by self-administration of capsule(s) and then at 2 hours self-test again and record on a pre-print sheet the test strip color.

Upon the return visit, patients will be crossed over after a 4 week wash out and given the other test group combination.

After 60 days of each combination, placebo and active, patients will repeat the IIEF questionnaire, EHS Score questionnaire and the Quality of Life survey.

The remaining product will be collected, and patients released from the study. Data will be collected on Case Report Forms.

Conditions

Erectile Dysfunction

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Nitric Oxide

Upon enrollment, patients will complete the IIEF questionnaire, EHS Score questionnaire and the Quality of Life survey.

Patients will be sent home with instructions to take 2 Berkeley Life capsules once daily (in this case Active NO), in combination with their existing treatment protocol (Tadalafil) and then return on day 60, returning all unused test product.

After 60 days of taking the active ingredient + tadalafil, patients will repeat the IIEF questionnaire, EHS Score questionnaire and the Quality of Life survey.

After a 4 week wash out, patients will be crossed over to the placebo group and given the other combination.

After 60 days of both combinations, placebo and active, patients will repeat the IIEF questionnaire, EHS Score questionnaire and the Quality of Life survey

Group Type: ACTIVE_COMPARATOR

Nitric Oxide

Intervention Type: DIETARY_SUPPLEMENT

Naturally produced and found in many different kinds of cells and organ systems, NO is an integral molecule in regulating blood pressure and maintaining a healthy cardiovascular system. NO produced or generated in the vasculature then diffuses into the underlying smooth muscle causing these muscles to relax. This results in vasodilation, causing a reduction in systemic blood pressure and an increase in blood flow and oxygen delivery to specific vascular beds.

Tadalafil

Intervention Type: DRUG

Vasodilator which treats erectile dysfunction and enlarged prostate (benign prostatic hyperplasia). It can also treat high blood pressure in the lungs (pulmonary arterial hypertension).

Placebo

Upon enrollment, patients will complete the IIEF questionnaire, EHS Score questionnaire and the Quality of Life survey.

Patients will be sent home with instructions to take 2 Berkeley Life capsules once daily (in this case the placebo), in combination with their existing treatment protocol (Tadalafil) and then return on day 60, returning all unused test product.

After 60 days of taking the placebo + tadalafil, patients will repeat the IIEF questionnaire, EHS Score questionnaire and the Quality of Life survey.

After a 4 week wash out, patients will be crossed over to the active group and given the other combination.

After 60 days of each combination, placebo and active, patients will repeat the IIEF questionnaire, EHS Score questionnaire and the Quality of Life survey

Group Type: PLACEBO_COMPARATOR

Tadalafil

Intervention Type: DRUG

Vasodilator which treats erectile dysfunction and enlarged prostate (benign prostatic hyperplasia). It can also treat high blood pressure in the lungs (pulmonary arterial hypertension).

Placebo

Intervention Type: OTHER

Nitric Oxide Placebo Compound

Interventions

Nitric Oxide

Naturally produced and found in many different kinds of cells and organ systems, NO is an integral molecule in regulating blood pressure and maintaining a healthy cardiovascular system. NO produced or generated in the vasculature then diffuses into the underlying smooth muscle causing these muscles to relax. This results in vasodilation, causing a reduction in systemic blood pressure and an increase in blood flow and oxygen delivery to specific vascular beds.

Intervention Type: DIETARY_SUPPLEMENT

Tadalafil

Vasodilator which treats erectile dysfunction and enlarged prostate (benign prostatic hyperplasia). It can also treat high blood pressure in the lungs (pulmonary arterial hypertension).

Intervention Type: DRUG

Placebo

Nitric Oxide Placebo Compound

Intervention Type: OTHER

Other Intervention Names

Berkeley Life

Eligibility Criteria

Inclusion Criteria

• Subjects Male between the ages of 40 and 65
• Subjects looking to support healthy sexual function who have been undergoing treatment to support healthy erections for at least 90 days with unsatisfactory results and whose nitric oxide levels are suboptimal based on an easy-to-use, self-check saliva strip that provides immediate, real-time, actionable feedback.
• Patients who are able to sign informed consent.

Exclusion Criteria

• Patients who are not considered medically stable (history of drug or alcohol dependency or having experienced health issues which could prevent experiencing a healthy erection).
• Patients with any known allergy to ingredients of capsule.
• Patients currently taking organic nitrates for acute angina
• Patients who do not or cannot tolerate PDE5 inhibitors
• Patients are unwilling or unable to provide informed consent.

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

RHA Investments Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Steven Bauer

Role: PRINCIPAL_INVESTIGATOR

Onsite Clinical Solutions

Locations

OnSite Clinical Solutions

Charlotte, North Carolina, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Rebecca Holland, MD

Role: CONTACT

rebecca@berkeleylife.com

3476326963

Trish Lally

Role: CONTACT

trish.lally@lifes2good.com

00353 86 8735603

Facility Contacts

Steven Bauer, MD

Role: primary

steve@ballantynemedical.com

800-785-3150 ext. 131

Elizabeth Allison

Role: backup

contracts@onsiteclinical.com

800-785-3150 ext. 131

Other Identifiers

#EDSupp23

Identifier Type: -

Identifier Source: org_study_id